Mantle Cell Lymphoma (MCL) (BSH 2023)

t(11;14) --> overexpression of Cyclin D1--> deregulation of cell cycle at G1-S phase boundary

Immunohist: Cyclin D1+, BCL2+, SOX11+, BCL6-

Flow: CD19+, CD20+, CD5+, FMC7+, Surface Ig+, CD10-, CD23-, CD200-

Mantle+cell-1.jpg

 

Intro

3-10% of NHL

Median age 60-65 years old

Male > Female

Worst features of low and high grade lymphoma. Incurable by standard therapy

Median survival 4-5 years in all comers (8-12 years in younger, fitter patients) (5-yr OS 58% in this 2023 paper)

CNS relapse occurs in 4-8% - usually leptomeningeal and within 2 years

 

Clinical Presentation


>90% present with Stage 3-4 disease

Splenomegaly, bone marrow infiltration and leukaemic involvement are common

30-50% of patients have >2 extranodal sites involved – esp. GI and liver

Variable clinical course – aggressive blastoid variant or indolent disease

 

DIAGNOSIS


Sample

  • Excision or core biopsy, or peripheral blood flow if leukaemic

Peripheral Blood Morphology

  • Small to intermediate sized cells with irregular, cleaved nuclei

  • Larger atypical forms in blastoid variants

Immunophenotype

  • CD19+, CD20+, CD5+, CD79b+, CD22+, FMC7+, ROR1+, Surface Ig+ (usually lambda)

  • CD10-, CD23-, CD200-

  •  Aberrant phenotypes – many variants including cyclin D1 neg, CD10 pos or CD5 neg

Histology

  • Variable - classic, blastoid, pleomoprhic, marginal zone-like and small cell types described

  • Ki67 proliferation index is a prognostic factor (>30% correlates w/ poor outcomes)

  • Immunohisto: Cyclin D1+, often SOX11+ (more details in guideline)

Cytogenetics

  • t(11;14)(q13;q32) (—> Cyclin D1 overexpression) can be detected by FISH

  • If Cyclin D1 negative then molecular testing required

  • Additional features: loss of 1p, 6q, 8p, 9p, 10p, 11q, 13p, 17p

  • Additional features: gains of 7p, 3q, 8q, 12q, 18q

Molecular

  • ATM most frequent mutation

  • TP53 mutation strongest predictor of poor outcomes (treatment response, early progression, mortality)

  • Others: NOTCH1, CDKN2A, CCND1, NSD2, KMT2A, S1PR1, CARD11

  • CCND2 and CCND3 mutation testing for Cyclin D1 negative cases

 

MCL in situ

  • syn. Mantle Cell Neoplasia – CD5+, Cyclin D1+ small lymphocytes in the mantle zone of follicles in morphologically reactive lymph nodes. Low risk of progression to clinical disease.

 

Differential Diagnosis of Cyclin D1+ haem malignancies:

  • Hairy Cell Leukaemia

  • Myeloma

  • Diffuse Large B Cell Lymphoma

 

INVESTIGATIONS / work-up

 

Bloods

  • FBC, Film, Flow cytometry

  • U&E, LFT, LDH, Urate

  • HIV, Hep B/C

 

Staging

  • PET-CT preferred (superior to CT in detecting nodal and splenic invovlement)

  • BM involved in 50-90% of cases. Biopsy recommended as PET-CT has poor detection rates

  • GI tract involved in 15-30% of cases. Routine endoscopy unlikely to affect management. Consider OGD for patients otherwise thought to be early stage headed for radiotherapy.

  • CNS involvement incommon at diagnosis. MRI + CSF only if symptoms to indicate.

 

Frailty assessment

  • Frailty affects response and risks of intensive treatement

  • Consider use of “Geriatric 8” or “Geriatric Assessment in Haematology” tools

Fertility assessment

  • Discuss where relevant

 

Prognostic Scores


MIPI (Mantle Cell IPI), s-MIPI, MIPI-B and MIPI-C all provide prognostic information but do not currently affect treatment decisions. MIPI was predictive of OS and PFS in MCL2 trial.

MIPI Score

  • Uses age, ECOG PS, LDH ratio to ULN and WBC

 

MANAGEMENT

 

1st Line Management

 

Stage I/IIa

  • 5% of cases. Limited evidence available.

  • Include endoscopy, BM biopsy and PET-CT in staging investigations to confirm early stage

  • Options: W&W versus localized involved field radiotherapy (60-80% CR w/ possible cure)

 

Stage III/IV, Indolent Disease

  • 10-15% of cases

  • Typically non-nodal with IGHV-mutated and SOX11-negative or nodal with a low Ki-67

  • Can W&W closely, defers treatment by median of 12 months

  • Indications to treat include: Bulky LN, B symptoms, Symptomatic organomegaly, BM failure

 

Stage III/IV, Fit for autograft

  • Typically <65 yo

  • No specific induction regimen superior, but should include rituximab and high dose cytarabine

  • e.g. R-Maxi-CHOP/cytarabine (NORDIC Protocol) --> Autograft in 1st CR

  • e.g. R-DHAP x4 (LyMa Trial) --> Autograft in 1st CR

  • Autograft significantly prolongs PFS, not clear that it improves OS.

  • R-maintenance post autograft 2-monthly for 3 years

    • Proven benefit after R-CHOP / R-DHAP (4-year PFS 85% / OS 89% vs 64/80% w/out)

  • Addition of ibrutinib to induction and maintenance is beneficial but not currently available in UK (2023)

  • TP53 patients very poor outcomes with the above. Consider clinical trial to access alternative strategies, e.g. upfront CAR-T

 

Stage III/IV, Older/Less fit

  • Consider using “Geriatric 8” or “Geriatric Assessment in Haematology” to aid assessment

  • R-CHOP / R-Bendamustine / R-BAC / VR-CAP

  • R-maintenance 2-monthly until progression (funding restricts to a maximum 2 years)

    • Proven benefit post R-CHOP with prolonged PFS (and OS in some studies)

    • No benefit demonstrated post R-Benda in original trials. Subsequent real world evidence indicates a benefit and should be offered.

 

Assessing Treatment Response

 

Assess response with an end of treatment imaging - PET-CT or CT 

Minimal residual disease (MRD) monitoring of t(11;14) by PCR may predict relapse but is not currently in routine use.

 

relapse/refractory management

 

Excluding transplant, 1st relapse has median survival of 1-2 years

Fit, high-risk patients should be considered for CAR-T

  • Re-biopsy for histological subtype, Ki-67 and TP53 mutations

  • Refer to CAR-T centre at start of BTKi

  • Close monitoring Re-image 8-12 weeks after starting BTKi

 

Ibrutinib

  • Approved for 2nd line use (NICE 2018)

  • Most active single agent in relapsed MCL – 68% response rate, 21% CR.

  • Also shown efficacy in CNS relapse

  • Other BTKi’s not currently available in UK (2023)

CAR-T

  • Brexucabtagene autoleucel (brexu-cel) - autogolous, CD19-targeting CAR-T

  • Approved for use after 2+ lines of treatment including a BTKi (NICE 2021)

  • If fit for CAR-T, pts should undergo interim imaging after 8-12 weeks of BTKi

Post-BTKi and Post/not-fit CAR-T

  • Consider clinical trial where possible

  • R-CHOP / R-Benda / R-BAC, whichever not used previously

  • Non-covalent BTK Inhibitors, pirtobrutinib, if available

  • Bortezomib, Temsirolimus & lenalidomide are all licensed for relapsed MCL

  • Venetoclax looks active in phase 1 trial

 

Allogenic Transplant?

  • Consider for fit patients following immunochemotherapy, BTKi and CAR-T

A few trial notes

TRIANGLE 2022

870 patients <65 yo, untreated mantle cell lymphoma

Addition of ibrutinib to induction and maintenance

3 arms: Autograft, Autorgaft + Ibrutinib, Ibrutinib

Outcomes superior in ibrutinib arms - not currently available in UK for this indication (2023)

ZUMA-2 2020

Phase 2, 74 patients, CAR-T for R/R mantle cell. Up to 5 prev therapies, including a BTKi

12 month PFS 61%

12 month OS 83%

LyMa TRIAL 2017

299 patients, R-DHAPx4, followed by BEAM Autograft (R-CHOPx4 given is not in CR/PR post DHAP)

The R-DHAP could be with cisplatin or oxalaplatin

Post autograft, randomised to rituximab maintenance or not

4-year OS 78%, PFS 67% and superior in the R-maintenance arm

MCL Younger 2016

Phase 3, open label. 500 patients <65yo with untreated mantle cell

2 arms: R-CHOP x6 + Autograft versus R-CHOP/R-DHAP alternating x6 + Autograft

Median time to treatment failure: 9.1 yrs cytarabine vs 3.9 yrs without

NORDIC MCL2 STUDY 2008

Alternating cycles of R-Maxi-CHOP and High dose cytarabine for 6 cycles, followed by autograft

5-year EFS >60%

2016 update: No plateau in the survival curve, with ongoing late relapse events

2016 update: 40% of low and intermediate risk patients still in 1st remission at 12 years